Glembatumumab vedotin Uses, Dosage, Side Effects and more

A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.

Attribute	Details
Trade Name	Glembatumumab vedotin
Generic	Glembatumumab vedotin
Glembatumumab vedotin Other Names	Glembatumumab vedotin
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	January 7, 2025 at 1:49 am

Uses

Investigated for use/treatment in melanoma.

How Glembatumumab vedotin works

CR011 is a fully-human monoclonal antibody which utilizes antibody-drug conjugation (ADC) technology licensed from Seattle Genetics. The ADC technology links vcMMAE, a potent chemotherapeutic, to the CR011 antibody resulting in the antibody-drug conjugate CR011-vcMMAE. CR011-vcMMAE targets GPNMB, a protein located specifically on the surface of melanoma cells. After CR011-vcMMAE binds to GPNMB, it is transported inside the cancer cell where the chemotherapy payload, Auristatin E, is cleaved from the antibody and activated.

Innovators Monograph